Efficacy and Safety of Upadacitinib in Elderly Patients with Inflammatory Bowel Disease: A Multicenter Real-World Study

Study on the Role and Mechanism of Del-1 in Regulating Metabolic Reprogramming of Intestinal Stem Cells During Inflammation Resolution in IBD——Efficacy and Safety of Upadacitinib in Elderly Patients with Inflammatory Bowel Disease: A Multicenter Real-World Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500113468

Enrollment

Unknown

Registered

2025-11-28

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

exposure group:None

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnosis of moderate to severe Crohn's disease or ulcerative colitis; 2.Initiation of upadacitinib treatment after diagnosis.

Exclusion criteria

Exclusion criteria: 1.Use of upadacitinib for conditions other than IBD;

Design outcomes

Primary

Measure	Time frame
Clinical remission rate;	—

Secondary

Measure	Time frame
Exposure-Adjusted Incidence Rate;Endoscopic Remission Rate;Endoscopic Response Rate;Clinical Response Rate;	—

Countries

China

Contacts

Public ContactYu Fu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

futureyu@hust.edu.cn+86 13907194622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026